Presentation, management, and outcomes of STEMI in Egypt: results from the European Society of Cardiology Registry on ST elevation myocardial infarction.
Egypt
Networks
Primary PCI
Registry
Reperfusion
STEMI
Thrombolytic
Journal
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology
ISSN: 2090-911X
Titre abrégé: Egypt Heart J
Pays: Germany
ID NLM: 9106952
Informations de publication
Date de publication:
01 Jul 2020
01 Jul 2020
Historique:
received:
08
04
2020
accepted:
10
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Apart from few small single-center studies, there are limited data about STEMI patients in Egypt. Nineteen Egyptian centers (with and without PCI facilities) participated in this registry with 1356 patients who were compared to 7420 patients from other ESC countries. The aims of this study were to describe the characteristics of patients with STEMI, to assess STEMI management patterns particularly the current use of reperfusion therapies, to evaluate the organization of STEMI networks across Egypt, to evaluate in-hospital patient outcome, and to compare Egyptian patients with other ESC countries. Compared to other ESC countries, Egyptian patients were younger (mean age 55.4 ± 11.3 vs. 62.9 ± 12.4; p < 0.001 and 4.36% vs. 19.41%% were ≥ 75 years old; p < 0.001) with fewer females (18.44% vs. 25.63%; p < 0.001). Egypt had longer median time between symptoms onset and first medical contact: 120.0 (60.0; 240.0) vs.100.0 (50.0; 240.0) p < 0.001. Self-presentation rather than EMS presentation was the mode of admission in 86.06% in Egypt vs. 25.83% in EU countries (p < 0.001). On qualifying ECG, anterior STEMI was in 57.08% in Egypt vs. 45.98% in other countries (p < 0.001). Initial reperfusion therapy was 49.12%, 43.07%, and 7.26% for primary PCI, thrombolytic therapy and no reperfusion in Egypt vs. 85.42%, 7.26%, and 7.82% for EU countries, respectively. In-hospital mortality was 4.65% in Egypt vs. 3.50% in other countries p 0.040 and was 18.87% in no reperfusion vs. 2.10% in primary PCI vs. 4.97% in thrombolysis (p < 0.001) among Egyptians. Patients were discharged on aspirin in 98.61%, clopidogrel in 91.07%, ticagrelor in 7.31%, DAPT in 97.69%, beta blockers in 82.83%, ACE inhibitors in 84.76%, MRAs in 10.01%, and statins in 99.77%. Compared to other ESC countries, Egyptian STEMI patients were younger, more frequently current smokers and diabetics, and had longer time between symptoms onset and first medical contact with more self-presentation rather than EMS presentation. Thrombolytic therapy is still a common reperfusion therapy in Egypt while primary PCI was offered to half of the patients. In-hospital mortality was significantly higher in Egypt and was highest among no reperfusion patients and lowest among PPCI patients.
Sections du résumé
BACKGROUND
BACKGROUND
Apart from few small single-center studies, there are limited data about STEMI patients in Egypt. Nineteen Egyptian centers (with and without PCI facilities) participated in this registry with 1356 patients who were compared to 7420 patients from other ESC countries. The aims of this study were to describe the characteristics of patients with STEMI, to assess STEMI management patterns particularly the current use of reperfusion therapies, to evaluate the organization of STEMI networks across Egypt, to evaluate in-hospital patient outcome, and to compare Egyptian patients with other ESC countries.
RESULTS
RESULTS
Compared to other ESC countries, Egyptian patients were younger (mean age 55.4 ± 11.3 vs. 62.9 ± 12.4; p < 0.001 and 4.36% vs. 19.41%% were ≥ 75 years old; p < 0.001) with fewer females (18.44% vs. 25.63%; p < 0.001). Egypt had longer median time between symptoms onset and first medical contact: 120.0 (60.0; 240.0) vs.100.0 (50.0; 240.0) p < 0.001. Self-presentation rather than EMS presentation was the mode of admission in 86.06% in Egypt vs. 25.83% in EU countries (p < 0.001). On qualifying ECG, anterior STEMI was in 57.08% in Egypt vs. 45.98% in other countries (p < 0.001). Initial reperfusion therapy was 49.12%, 43.07%, and 7.26% for primary PCI, thrombolytic therapy and no reperfusion in Egypt vs. 85.42%, 7.26%, and 7.82% for EU countries, respectively. In-hospital mortality was 4.65% in Egypt vs. 3.50% in other countries p 0.040 and was 18.87% in no reperfusion vs. 2.10% in primary PCI vs. 4.97% in thrombolysis (p < 0.001) among Egyptians. Patients were discharged on aspirin in 98.61%, clopidogrel in 91.07%, ticagrelor in 7.31%, DAPT in 97.69%, beta blockers in 82.83%, ACE inhibitors in 84.76%, MRAs in 10.01%, and statins in 99.77%.
CONCLUSION
CONCLUSIONS
Compared to other ESC countries, Egyptian STEMI patients were younger, more frequently current smokers and diabetics, and had longer time between symptoms onset and first medical contact with more self-presentation rather than EMS presentation. Thrombolytic therapy is still a common reperfusion therapy in Egypt while primary PCI was offered to half of the patients. In-hospital mortality was significantly higher in Egypt and was highest among no reperfusion patients and lowest among PPCI patients.
Identifiants
pubmed: 32607863
doi: 10.1186/s43044-020-00069-x
pii: 10.1186/s43044-020-00069-x
pmc: PMC7326745
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Subventions
Organisme : European Society of cardiology
ID : 12000 euro
Références
Eur Heart J. 2018 Feb 14;39(7):508-579
pubmed: 29190377
Lancet. 2017 Aug 19;390(10096):747-759
pubmed: 28831992
Eur Heart J. 2016 Aug;37(31):2449-53
pubmed: 27558321
Glob Heart. 2014 Dec;9(4):419-23
pubmed: 25592795
Circulation. 2006 May 23;113(20):2398-405
pubmed: 16702474
Cardiol Res. 2017 Oct;8(5):190-198
pubmed: 29118880
Circulation. 2007 Aug 14;116(7):721-8
pubmed: 17673457
Circulation. 2014 Apr 22;129(16):1629-36
pubmed: 24657993
Open Heart. 2015 May 21;2(1):e000240
pubmed: 26019883
N Engl J Med. 2013 Apr 11;368(15):1379-87
pubmed: 23473396
Eur Heart J. 2010 Apr;31(8):943-57
pubmed: 19933242
PLoS One. 2016 Jan 25;11(1):e0147385
pubmed: 26807577
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Circulation. 2007 Aug 14;116(7):729-36
pubmed: 17673456
Eur Heart J. 2012 May;33(10):1232-40
pubmed: 22041553
Eur Heart J. 2014 Aug 1;35(29):1957-70
pubmed: 24419804
Ann Saudi Med. 2012 Jan-Feb;32(1):9-18
pubmed: 22156634
Heart. 2012 Jan;98(1):15-7
pubmed: 22076013
Indian Heart J. 2016 Mar-Apr;68(2):169-73
pubmed: 27133326
Am Heart J. 2011 Nov;162(5):852-859.e22
pubmed: 22093201
JAMA. 2007 Nov 28;298(20):2371-80
pubmed: 17982184
Eur Heart J. 2017 Jan 14;38(3):138-139
pubmed: 28158502